On the possible role of xanthine resistant receptors/sites in the bronchodilator action of adenosine

L. Brugos, R. Gesztelyi, J. Zsuga, A. Cseppento, Z. Galajda, S. Sipka, M. Szilasi, I. Edes, J. A. Szentmiklosi (Debrecen, Hungary)

Source: Annual Congress 2005 - Exploring alternative mechanisms and treatments
Session: Exploring alternative mechanisms and treatments
Session type: Thematic Poster Session
Number: 3712
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
L. Brugos, R. Gesztelyi, J. Zsuga, A. Cseppento, Z. Galajda, S. Sipka, M. Szilasi, I. Edes, J. A. Szentmiklosi (Debrecen, Hungary). On the possible role of xanthine resistant receptors/sites in the bronchodilator action of adenosine. Eur Respir J 2005; 26: Suppl. 49, 3712

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Inhaled corticosteroids and leukotriene receptor antagonists induce protection against adenosine 5‘monophosphate induced bronchospasm in a synergic fashion
Source: Annual Congress 2007 - Current issues in airway physiology, pharmacology and monitoring
Year: 2007


Novel inhibitory effect on 5-lipoxygenase activity by montelukast. Evidence for a noncompetitive mode of action
Source: Eur Respir J 2004; 24: Suppl. 48, 96s
Year: 2004

Dose-related effects of formoterol on airway responsiveness to adenosine 5'-monophosphate and histamine
Source: Eur Respir J 2002; 19: 611-616
Year: 2002



The adenosine A2A-Receptor is not involved in adenosine induced bronchoconstriction in asthmatics
Source: Eur Respir J 2003; 22: Suppl. 45, 103s
Year: 2003

In vitro pharmacological characterization of the novel inhaled bronchodilator CHF6366 acting as dual muscarinic antagonist/ß2-agonist (MABA)
Source: International Congress 2017 – Bronchodilators and bronchoprotectors
Year: 2017

Dual mechanism of action of T2 inhibitor therapies in virally induced exacerbations of asthma: evidence for a beneficial counter-regulation
Source: Eur Respir J, 54 (1) 1802390; 10.1183/13993003.02390-2018
Year: 2019



Effects of histamine and leukotriene antagonism on mannitol and adenosine monophosphate (AMP) challenge
Source: Eur Respir J 2002; 20: Suppl. 38, 386s
Year: 2002

Protective effect of budesonide/formoterol in a model of repeated exposure to inhaled adenosine 5‘-monophosphate (AMP) in patients with asthma
Source: Eur Respir J 2007; 30: Suppl. 51, 353s
Year: 2007

Dual inhibition of thromboxane synthase and 5-lipoxygenase, potentially significant mechanism for the treatment of asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 264s
Year: 2001

Carrier-mediated disposal mechanisms for long-acting β2-agonists in the airway: the emerging role of corticosteroid sensitivity
Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD
Year: 2008

Involvement of angiotensins on bronchomotor effects of adenosine
Source: Annual Congress 2009 - Aspects of uncontrolled asthma
Year: 2009

Vilanterol, a novel inhaled long-acting β2 adrenoceptor agonist (LABA), demonstrates extensive first pass clearance to metabolites with negligible pharmacological activity in man
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I
Year: 2011

NIK-626; a dual inhibitor of thromboxane synthase and 5-lipoxygenase, potential candidate as a novel anti-asthma compound
Source: Eur Respir J 2001; 18: Suppl. 33, 264s
Year: 2001

Formoterol is more potent and more effective than salmeterol in the inhibition of oxidative burst in human eosinophils
Source: Eur Respir J 2001; 18: Suppl. 33, 49s
Year: 2001

PBF-680, an oral A1 adenosine receptor antagonist, inhibits adenosine monophosphate (AMP) airway hyperresponsiveness (AHR) in mild-to-moderate asthma: a Phase-IIa proof-of-concept trial
Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights
Year: 2020


Cyclic AMP mediates the anti-asthma properties of the lidocaine analog JMF2-1
Source: Annual Congress 2012 - The best of pharmacology treatment for asthma and COPD
Year: 2012


The inhaled anticholinergic agent, aclidinium bromide, reverses cholinergic-induced bronchoconstriction in guinea pigs with a fast onset of action and a long duration of effect
Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD
Year: 2008


Glycopyrrolate exerts medium-duration bronchodilator activity in guinea-pig and human airways
Source: Eur Respir J 2005; 26: Suppl. 49, 216s
Year: 2005

Effect of an inhaled adenosine A2A agonist on the allergen induced late asthmatic response
Source: Eur Respir J 2003; 22: Suppl. 45, 204s
Year: 2003

The dual PDE3/PDE4 phosphodiesterase inhibitor RPL554 produces more complete bronchodilator responses than the beta2-agonist salbutamol and the anti-muscarinic agent ipratropium bromide, alone and in combination, in guinea-pig isolated trachea
Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis
Year: 2015